Access to live human cancer tissue for functional molecular and biological analysis to improve translational cancer research is extremely limited. The Segelov laboratory in collaboration with The Southey Laboratory and Victoria Cancer Biobanking (VCB) is establishing a living cancer biobanking platform. This aims to incorporate state-of-the-art patient-derived xenograft (PDX) models with the utility of genetically engineered/immunocompromised mice, to preserve tumour viability to be expanded for large scale cryopreservation. This project involves careful selection of human cancer tissue for subcutaneous implantation into NOD/SCID IL2Rynull(NSG) mice and the subsequent expansion of successfully engrafted tumours into large numbers of NSG mice. Successfully engrafted tumours will undergo extensive validation processes, including immuno-histopathological, functional and molecular analyses to confirm the retention of the original tumour biology. These tumours will then be cryopreserved for viable tumour tissue stockpiling (see diagram). The “Living Biobank” will be an invaluable resource for cancer research.
Biobanking, patient derived xenograft, cancer, biomarkers
School of Clinical Sciences at Monash Health / Hudson Institute of Medical Research
Monash Health Translation Precinct (Monash Medical Centre)